{"transactions":[{"id":778358,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T21:01:07.000Z","date":"2026-05-13","kind":"grant","planned":false,"acquired":true,"shares":2047,"price":90.35,"value":184946.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted by Issuer pursuant to the Ventas, Inc. 2022 Incentive Plan. The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the date of Issuer's 2027 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price per share of Issuer's common stock as of the grant date."}],"balance_after":26181,"source":{"system":"sec-edgar","filing":"0001569926-26-000012","document":"wk-form4_1778878864.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/740260/000156992626000012/wk-form4_1778878864.xml","form_type":"4"}},{"id":903710,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-17T22:00:44.000Z","date":"2020-07-21","kind":"purchase","planned":false,"acquired":true,"shares":37,"price":34.2143,"value":1265.9291,"ownership":{"direct":false,"nature":"By Family Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares acquired by the Elizabeth A. Nolan Dec of Trust."}],"balance_after":87,"source":{"system":"sec-edgar","filing":"0001569926-26-000010","document":"wk-form5_1771365641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/740260/000156992626000010/wk-form5_1771365641.xml","form_type":"5"}},{"id":903709,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-17T22:00:44.000Z","date":"2020-04-20","kind":"purchase","planned":false,"acquired":true,"shares":50,"price":27.6966,"value":1384.83,"ownership":{"direct":false,"nature":"By Family Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares acquired by the Elizabeth A. Nolan Dec of Trust."}],"balance_after":50,"source":{"system":"sec-edgar","filing":"0001569926-26-000010","document":"wk-form5_1771365641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/740260/000156992626000010/wk-form5_1771365641.xml","form_type":"5"}},{"id":903708,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-17T22:00:44.000Z","date":"2020-07-21","kind":"purchase","planned":false,"acquired":true,"shares":27,"price":34.2141,"value":923.7807,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares acquired by the Nolan Family Investments LLC."}],"balance_after":63,"source":{"system":"sec-edgar","filing":"0001569926-26-000010","document":"wk-form5_1771365641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/740260/000156992626000010/wk-form5_1771365641.xml","form_type":"5"}},{"id":903707,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-17T22:00:44.000Z","date":"2020-04-20","kind":"purchase","planned":false,"acquired":true,"shares":36,"price":27.6964,"value":997.0704,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares acquired by the Nolan Family Investments LLC."}],"balance_after":36,"source":{"system":"sec-edgar","filing":"0001569926-26-000010","document":"wk-form5_1771365641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/740260/000156992626000010/wk-form5_1771365641.xml","form_type":"5"}},{"id":930577,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:07.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":41312,"price":4.61,"value":190448.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive."}],"balance_after":2908257,"source":{"system":"sec-edgar","filing":"0001569926-26-000008","document":"form4-01272026_040103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000156992626000008/form4-01272026_040103.xml","form_type":"4"}},{"id":930576,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:07.000Z","date":"2026-01-23","kind":"sale","planned":false,"acquired":false,"shares":136789,"price":4.75,"value":649747.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":2949569,"source":{"system":"sec-edgar","filing":"0001569926-26-000008","document":"form4-01272026_040103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000156992626000008/form4-01272026_040103.xml","form_type":"4"}},{"id":939688,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-14T21:45:09.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":648000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":648000,"derivative":{"exercise_price":4.86,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":648000},"source":{"system":"sec-edgar","filing":"0001569926-26-000002","document":"form4-01142026_040103.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000156992626000002/form4-01142026_040103.xml","form_type":"4"}},{"id":939687,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:09.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":1008000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":3086358,"source":{"system":"sec-edgar","filing":"0001569926-26-000002","document":"form4-01142026_040103.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000156992626000002/form4-01142026_040103.xml","form_type":"4"}},{"id":1148529,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T20:54:10.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":2882,"price":64.18,"value":184966.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted by Issuer pursuant to the Ventas, Inc. 2022 Incentive Plan. The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the date of Issuer's 2026 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price per share of Issuer's common stock as of the grant date."}],"balance_after":24134,"source":{"system":"sec-edgar","filing":"0000740260-25-000175","document":"wk-form4_1747342442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/740260/000074026025000175/wk-form4_1747342442.xml","form_type":"4"}},{"id":1317457,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-03T22:38:40.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":892500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":892500,"derivative":{"exercise_price":1.85,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":892500},"source":{"system":"sec-edgar","filing":"0001415889-25-000599","document":"form4-01032025_100137.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000599/form4-01032025_100137.xml","form_type":"4"}},{"id":1317456,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-03T22:38:40.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":892500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":2078358,"source":{"system":"sec-edgar","filing":"0001415889-25-000599","document":"form4-01032025_100137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000599/form4-01032025_100137.xml","form_type":"4"}},{"id":1515312,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T21:01:46.000Z","date":"2024-05-14","kind":"grant","planned":false,"acquired":true,"shares":3648,"price":47.96,"value":174958.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted by Issuer pursuant to the Ventas, Inc. 2022 Incentive Plan. The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the date of Issuer's 2025 Annual Meeting of Stockholders."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price per share of Issuer's common stock as of the date of the grant."}],"balance_after":21252,"source":{"system":"sec-edgar","filing":"0000740260-24-000162","document":"wk-form4_1715893277.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/740260/000074026024000162/wk-form4_1715893277.xml","form_type":"4"}},{"id":1689761,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-04T21:41:35.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":1184688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1184688,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":1184688},"source":{"system":"sec-edgar","filing":"0001209191-24-000807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000807/doc4.xml","form_type":"4"}},{"id":1689760,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-04T21:41:35.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":1184688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1185858,"source":{"system":"sec-edgar","filing":"0001209191-24-000807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000807/doc4.xml","form_type":"4"}},{"id":1708249,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-12-18T21:46:29.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":466550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":466550,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":466550},"source":{"system":"sec-edgar","filing":"0001209191-23-058971","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123058971/doc4.xml","form_type":"4"}},{"id":1806745,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-17T00:52:21.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":444444,"price":0.9,"value":399999.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Nolan Capital, LLC (the \"LLC\"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC."}],"balance_after":1535545,"source":{"system":"sec-edgar","filing":"0001209191-23-046150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123046150/doc4.xml","form_type":"4"}},{"id":1887957,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-18T20:48:32.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":3835,"price":45.63,"value":174991.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted by Issuer pursuant to the Ventas, Inc. 2022 Incentive Plan. The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":17604,"source":{"system":"sec-edgar","filing":"0000740260-23-000123","document":"wf-form4_168444289623867.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/740260/000074026023000123/wf-form4_168444289623867.xml","form_type":"4"}},{"id":2070864,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-04T21:51:28.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":1106131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the option shall vest and become exercisable on December 16, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1106131,"derivative":{"exercise_price":2.26,"expiration_date":"2032-12-30","underlying":"Common Stock","underlying_shares":1106131},"source":{"system":"sec-edgar","filing":"0001209191-23-001020","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123001020/doc4.xml","form_type":"4"}},{"id":2224674,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T20:38:26.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 17, 2023 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director though the applicable vesting date."}],"balance_after":15500,"derivative":{"exercise_price":2.81,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-22-038689","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122038689/doc4.xml","form_type":"4"}},{"id":2288438,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T20:50:01.000Z","date":"2022-04-27","kind":"grant","acquired":true,"shares":3056,"price":57.25,"value":174956.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock granted by Issuer pursuant to the Ventas, Inc. 2012 Incentive Plan. The restricted stock vests in two equal annual installments on the date of the Issuer's 2023 Annual Meeting of Stockholders and the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":13769,"source":{"system":"sec-edgar","filing":"0000740260-22-000111","document":"wf-form4_165126533152098.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/740260/000074026022000111/wf-form4_165126533152098.xml","form_type":"4"}},{"id":2662324,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-21T21:02:47.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":15500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the earlier of June 17, 2022 or the next annual stockholders meeting, subject to continued service as a director though the applicable vesting date."}],"balance_after":15500,"derivative":{"exercise_price":25.04,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":15500},"source":{"system":"sec-edgar","filing":"0001209191-21-042107","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121042107/doc4.xml","form_type":"4"}},{"id":2694412,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-27T21:28:55.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":3158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock granted by Issuer pursuant to the Ventas, Inc. 2012 Incentive Plan. The restricted stock vests in two equal annual installments on the date of the Issuer's 2022 Annual Meeting of Stockholders and the date of the Issuer's 2023 Annual Meeting of Stockholders."}],"balance_after":10713,"source":{"system":"sec-edgar","filing":"0000740260-21-000134","document":"wf-form4_162215084775256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/740260/000074026021000134/wf-form4_162215084775256.xml","form_type":"4"}},{"id":2699913,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-24T12:39:46.000Z","date":"2021-05-20","kind":"purchase","acquired":true,"shares":1170,"price":22.35,"value":26149.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.04 to $22.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":1170,"source":{"system":"sec-edgar","filing":"0001209191-21-035165","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121035165/doc4.xml","form_type":"4"}},{"id":3020356,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-30T20:38:44.000Z","date":"2020-09-28","kind":"exercise","acquired":false,"shares":1470,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Nolan Capital, LLC (the \"LLC\"). The Reporting Person is the President of LLC, and is deemed to have sole voting and investment power with respect to the securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1601},"source":{"system":"sec-edgar","filing":"0001209191-20-052462","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052462/doc4.xml","form_type":"4"}},{"id":3020355,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-09-30T20:38:44.000Z","date":"2020-09-28","kind":"exercise","acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Nolan Capital, LLC (the \"LLC\"). The Reporting Person is the President of LLC, and is deemed to have sole voting and investment power with respect to the securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1089500},"source":{"system":"sec-edgar","filing":"0001209191-20-052462","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052462/doc4.xml","form_type":"4"}},{"id":3020354,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-30T20:38:44.000Z","date":"2020-09-28","kind":"exercise","acquired":true,"shares":1601,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Nolan Capital, LLC (the \"LLC\"). The Reporting Person is the President of LLC, and is deemed to have sole voting and investment power with respect to the securities."}],"balance_after":1091101,"source":{"system":"sec-edgar","filing":"0001209191-20-052462","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052462/doc4.xml","form_type":"4"}},{"id":3020353,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-30T20:38:44.000Z","date":"2020-09-28","kind":"exercise","acquired":true,"shares":1089500,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Nolan Capital, LLC (the \"LLC\"). The Reporting Person is the President of LLC, and is deemed to have sole voting and investment power with respect to the securities."}],"balance_after":1089500,"source":{"system":"sec-edgar","filing":"0001209191-20-052462","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052462/doc4.xml","form_type":"4"}},{"id":3022674,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-09-25T21:13:44.000Z","date":"2020-09-23","kind":"grant","acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option vest in 36 equal monthly installments, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":31000,"derivative":{"exercise_price":20,"expiration_date":"2030-09-23","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001209191-20-052115","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052115/doc4.xml","form_type":"4"}},{"id":3141812,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-20T20:53:25.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":5424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock granted by Issuer pursuant to the Ventas, Inc. 2012 Incentive Plan. This restricted stock vests in two equal annual installments on the date of the Issuer's 2021 Annual Meeting of Stockholders and the date of the Issuer's 2022 Annual Meeting of Stockholders."}],"balance_after":7555,"source":{"system":"sec-edgar","filing":"0000740260-20-000110","document":"wf-form4_159000798787099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/740260/000074026020000110/wf-form4_159000798787099.xml","form_type":"4"}},{"id":3157925,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-07T20:25:33.000Z","date":"2020-05-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":12.84,"expiration_date":"2030-05-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-027679","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000120919120027679/doc4.xml","form_type":"4"}},{"id":3393636,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-10-15T20:45:08.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":22000,"derivative":{"exercise_price":2.82,"expiration_date":"2029-10-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000899243-19-025572","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000089924319025572/doc4.xml","form_type":"4"}},{"id":3454883,"issuer":{"id":3044,"kind":"organization","name":"Ventas, Inc.","symbol":"VTR"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-29T20:58:20.000Z","date":"2019-07-26","kind":"grant","acquired":true,"shares":2131,"price":67.03,"value":142840.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock granted by Issuer pursuant to the Ventas, Inc. 2012 Incentive Plan. This restricted stock vests in two equal annual installments beginning on the first anniversary of the date of the grant."}],"balance_after":2131,"source":{"system":"sec-edgar","filing":"0000740260-19-000142","document":"wf-form4_156443388352571.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/740260/000074026019000142/wf-form4_156443388352571.xml","form_type":"4"}},{"id":3932989,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:38:33.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":133.8,"expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001209191-18-030127","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030127/doc4.xml","form_type":"4"}},{"id":3932988,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:38:33.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":77.24,"expiration_date":"2027-05-10","underlying":"Common Stock","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0001209191-18-030127","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030127/doc4.xml","form_type":"4"}},{"id":3932987,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:38:33.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":42.61,"expiration_date":"2026-06-20","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-18-030127","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030127/doc4.xml","form_type":"4"}},{"id":3932986,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T12:38:33.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":728300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option."}],"balance_after":0,"derivative":{"exercise_price":15.94,"expiration_date":"2025-06-10","underlying":"Common Stock","underlying_shares":728300},"source":{"system":"sec-edgar","filing":"0001209191-18-030127","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030127/doc4.xml","form_type":"4"}},{"id":3932985,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-05-15T12:38:33.000Z","date":"2018-05-15","kind":"disposition_to_issuer","acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 11,000 shares underlying Restricted Stock Units (the \"RSUs\"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Novartis AG, a company organized under the laws of Switzerland (\"Parent\"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the \"Common Stock\") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the \"Offer Price\") in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-030127","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118030127/doc4.xml","form_type":"4"}},{"id":3940813,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-09T22:13:59.000Z","date":"2018-05-07","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 7, 2018 (the \"Vesting Commencement Date\") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date."}],"balance_after":15000,"derivative":{"exercise_price":13.1,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-028974","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000120919118028974/doc4.xml","form_type":"4"}},{"id":3981967,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-27T17:26:19.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable as to 25% of the shares underlying the option on March 13, 2019; the remaining shares shall vest in 36 equal monthly installments beginning on April 13, 2019, subject to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":44000,"derivative":{"exercise_price":133.8,"expiration_date":"2028-03-13","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001209191-18-021776","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118021776/doc4.xml","form_type":"4"}},{"id":3981966,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-27T17:26:19.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest in 3 equal annual installments beginning on March 13, 2019, such that the restricted stock award will be fully vested on March 13, 2021, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":11000,"source":{"system":"sec-edgar","filing":"0001209191-18-021776","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118021776/doc4.xml","form_type":"4"}},{"id":4003471,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-09T17:04:01.000Z","date":"2018-03-07","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"184,575 shares vested and became exercisable on June 8, 2016; the remaining shares vest and become exercisable in 36 equal monthly installments thereafter until June 8, 2019, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":728300,"derivative":{"exercise_price":15.94,"expiration_date":"2025-06-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-18-018544","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118018544/doc4.xml","form_type":"4"}},{"id":4003470,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-09T17:04:01.000Z","date":"2018-03-07","kind":"sale","acquired":false,"shares":1100,"price":131.86,"value":145046.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.33 to $132.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-018544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118018544/doc4.xml","form_type":"4"}},{"id":4003469,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-09T17:04:01.000Z","date":"2018-03-07","kind":"sale","acquired":false,"shares":600,"price":130.78,"value":78468.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.32 to $131.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4."}],"balance_after":1100,"source":{"system":"sec-edgar","filing":"0001209191-18-018544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118018544/doc4.xml","form_type":"4"}},{"id":4003468,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-09T17:04:01.000Z","date":"2018-03-07","kind":"sale","acquired":false,"shares":4800,"price":129.66,"value":622368.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.23 to $130.225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4."}],"balance_after":1700,"source":{"system":"sec-edgar","filing":"0001209191-18-018544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118018544/doc4.xml","form_type":"4"}},{"id":4003467,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-09T17:04:01.000Z","date":"2018-03-07","kind":"sale","acquired":false,"shares":2400,"price":128.65,"value":308760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.21 to $129.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001209191-18-018544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118018544/doc4.xml","form_type":"4"}},{"id":4003466,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-09T17:04:01.000Z","date":"2018-03-07","kind":"sale","acquired":false,"shares":700,"price":127.65,"value":89355.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.17 to $127.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":8900,"source":{"system":"sec-edgar","filing":"0001209191-18-018544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118018544/doc4.xml","form_type":"4"}},{"id":4003465,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-09T17:04:01.000Z","date":"2018-03-07","kind":"sale","acquired":false,"shares":400,"price":126.65,"value":50660.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on November 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.15 to $126.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":9600,"source":{"system":"sec-edgar","filing":"0001209191-18-018544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118018544/doc4.xml","form_type":"4"}},{"id":4003464,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-09T17:04:01.000Z","date":"2018-03-07","kind":"exercise","acquired":true,"shares":10000,"price":15.94,"value":159400.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-18-018544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919118018544/doc4.xml","form_type":"4"}},{"id":4322800,"issuer":{"id":166664,"kind":"organization","name":"AveXis, Inc.","symbol":"AVXS"},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-05-12T18:23:17.000Z","date":"2017-05-10","kind":"grant","acquired":true,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable as to 25% of the shares underlying the option on May 10, 2018; the remaining shares shall vest in 36 equal monthly installments beginning on June 10, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":96000,"derivative":{"exercise_price":77.24,"expiration_date":"2027-05-10","underlying":"Common Stock","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0001209191-17-032145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652923/000120919117032145/doc4.xml","form_type":"4"}},{"id":4326637,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":47155,"kind":"person","name":"Nolan Sean P.","position":1,"cik":"0001569926","reported_name":"Nolan Sean P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-10T22:47:57.000Z","date":"2017-05-08","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 8, 2017 (the \"Vesting Commencement Date\") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date."}],"balance_after":9000,"derivative":{"exercise_price":13.74,"expiration_date":"2027-05-07","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-17-031405","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000120919117031405/doc4.xml","form_type":"4"}}]}